サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1442898

神経保護市場：世界の業界分析、規模、シェア、成長、動向、および予測、2023年～2031年

Neuroprotection Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2031
出版日: | 発行: Transparency Market Research | ページ情報: 英文 197 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.70円
神経保護市場：世界の業界分析、規模、シェア、成長、動向、および予測、2023年～2031年
出版日: 2024年01月19日
発行: Transparency Market Research
ページ情報: 英文 197 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

神経保護市場 - レポートの範囲

アルツハイマー病に関連する世界の認知症市場に関するTMRのレポートは、過去と現在の成長動向、および2023年から2031年の予測期間中に市場の指標の貴重な洞察を得る機会を研究しています。このレポートは、世界の認知症市場の収益を提供します。 2023年を基準年、2031年を予測年とみなして、2017年から2031年の期間のアルツハイマー病市場に関連付けられています。レポートは、2023年から2031年までの世界のアルツハイマー病に関連する認知症市場の複合年間成長率（CAGR %）も提供します。

このレポートは広範な調査を経て作成されました。1次調査では、調査活動の大部分が行われ、アナリストが主要なオピニオンリーダー、業界リーダー、オピニオンメーカーにインタビューを実施しました。2次調査には、アルツハイマー病市場に関連する認知症を理解するために、主要企業の製品文献、年次報告書、プレスリリース、および関連文書の参照が含まれます。

このレポートは、アルツハイマー病に関連する世界の認知症市場の競合情勢を詳しく掘り下げています。アルツハイマー病に関連する世界の認知症市場で活動する主要企業が特定され、これらのそれぞれがさまざまな属性の観点からプロファイルされています。会社概要、財務状況、最近の動向、 SWOTは、このレポートで概説されているアルツハイマー病に関連する世界の認知症市場の企業の属性です。

目次

第1章 エグゼクティブサマリー

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場概要

  • 市場セグメンテーション
  • 概要
  • 市場力学
  • 世界市場の分析と予測、2017～2031年

第5章 重要な洞察

  • パイプライン分析
  • 主要国の世界の病気の有病率と罹患率
  • COVID-19感染症のパンデミックが業界に与える影響

第6章 市場分析と予測：製品別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：製品別、2017年～2031年
    • フリーラジカル捕捉剤（抗酸化剤）
    • グルタミン酸アンタゴニスト（抗興奮毒性剤）
    • アポトーシス阻害剤
    • 抗炎症剤
    • 神経栄養因子（NTF）
    • 金属イオンキレート剤
    • 覚醒剤
    • その他
  • 市場の魅力度：製品別

第7章 世界市場の分析と予測：用途別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：用途別、2017年～2031年
    • 防止
    • 処理
  • 市場の魅力：用途別

第8章 世界市場の分析と予測：地域別

  • 主な調査結果
  • 市場金額予測：地域別、2017年～2031年
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場の魅力：地域別

第9章 北米市場の分析と予測

第10章 欧州市場の分析と予測

第11章 アジア太平洋市場の分析と予測

第12章 ラテンアメリカ市場の分析と予測

第13章 中東・アフリカ市場の分析と予測

第14章 競合情勢

  • 市場企業-競合マトリックス（企業の階層および規模別）
  • 市場シェア分析：企業別（2022年）
  • 企業プロファイル
    • Daiichi Sankyo Company
    • Eli Lilly and Company
    • AbbVie Inc.
    • Dr. Reddy's Laboratories Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Novartis AG
    • AstraZeneca plc.
    • Astrocyte Pharmaceuticals, Inc.
    • F. Hoffmann-La Roche AG
    • Biogen Inc.
図表

List of Tables

  • Table 01: Global Neuroprotection Market Value (US$ Mn) Forecast, By Product, 2017-2031
  • Table 02: Global Neuroprotection Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 03: Global Neuroprotection Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 04: North America Neuroprotection Market Value (US$ Mn) Forecast, By Product, 2017-2031
  • Table 05: North America Neuroprotection Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 06: North America Neuroprotection Market Value (US$ Mn) Forecast, by Country, 2023-2031
  • Table 07: Europe Neuroprotection Market Value (US$ Mn) Forecast, By Product, 2017-2031
  • Table 08: Europe Neuroprotection Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 09: Europe Neuroprotection Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 10: Asia Pacific Neuroprotection Market Value (US$ Mn) Forecast, By Product, 2017-2031
  • Table 11: Asia Pacific Neuroprotection Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 12: Asia Pacific Neuroprotection Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 13: Latin America Neuroprotection Market Value (US$ Mn) Forecast, By Product, 2017-2031
  • Table 14: Latin America Neuroprotection Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 15: Latin America Neuroprotection Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 16: Middle East & Africa Neuroprotection Market Value (US$ Mn) Forecast, By Product, 2017-2031
  • Table 17: Middle East & Africa Neuroprotection Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 18: Middle East & Africa Neuroprotection Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

List of Figures

  • Figure 01: Global Neuroprotection Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Global Neuroprotection Market Value Share Analysis, By Product 2022 and 2031
  • Figure 03: Global Neuroprotection Market Attractiveness Analysis, By Product, 2023-2031
  • Figure 04: Global Neuroprotection Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 05: Global Neuroprotection Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 06: Global Neuroprotection Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 07: Global Neuroprotection Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 08: North America Neuroprotection Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 09: North America Neuroprotection Market Value Share Analysis, By Product, 2022 and 2031
  • Figure 10: North America Neuroprotection Market Attractiveness Analysis, By Product, 2023-2031
  • Figure 11: North America Neuroprotection Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 12: North America Neuroprotection Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 13: North America Neuroprotection Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 14: North America Neuroprotection Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 15: Europe Neuroprotection Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 16: Europe Neuroprotection Market Value Share Analysis, By Product, 2022 and 2031
  • Figure 17: Europe Neuroprotection Market Attractiveness Analysis, By Product, 2023-2031
  • Figure 18: Europe Neuroprotection Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 19: Europe Neuroprotection Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 20: Europe Neuroprotection Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 21: Europe Neuroprotection Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 22: Asia Pacific Neuroprotection Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 23: Asia Pacific Neuroprotection Market Value Share Analysis, By Product 2022 and 2031
  • Figure 24: Asia Pacific Neuroprotection Market Attractiveness Analysis, By Product, 2023-2031
  • Figure 25: Asia Pacific Neuroprotection Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 26: Asia Pacific Neuroprotection Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 27: Asia Pacific Neuroprotection Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 28: Asia Pacific Neuroprotection Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 29: Latin America Neuroprotection Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 30: Latin America Neuroprotection Market Value Share Analysis, By Product, 2022 and 2031
  • Figure 31: Latin America Neuroprotection Market Attractiveness Analysis, By Product, 2023-2031
  • Figure 32: Latin America Neuroprotection Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 33: Latin America Neuroprotection Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 34: Latin America Neuroprotection Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 35: Latin America Neuroprotection Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 36: Middle East & Africa Neuroprotection Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 37: Middle East & Africa Neuroprotection Market Value Share Analysis, By Product, 2022 and 2031
  • Figure 38: Middle East & Africa Neuroprotection Market Attractiveness Analysis, By Product, 2023-2031
  • Figure 39: Middle East & Africa Neuroprotection Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 40: Middle East & Africa Neuroprotection Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 41: Middle East & Africa Neuroprotection Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 42: Middle East & Africa Neuroprotection Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 43: Global Neuroprotection Market Share Analysis, by Company, 2022
目次
Product Code: TMRGL40553

Neuroprotection Market - Scope of Report

TMR's report on the global dementia associated with Alzheimer's disease market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global dementia associated with Alzheimer's disease market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global dementia associated with Alzheimer's disease market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the dementia associated with Alzheimer's disease market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global dementia associated with Alzheimer's disease market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global dementia associated with Alzheimer's disease market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global dementia associated with Alzheimer's disease market.

The report delves into the competitive landscape of the global dementia associated with Alzheimer's disease market. Key players operating in the global dementia associated with Alzheimer's disease market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global dementia associated with Alzheimer's disease market profiled in this report.

Key Questions Answered in Global dementia associated with Alzheimer's disease Market Report:

  • What is the sales/revenue generated by dementia associated with Alzheimer's disease across all regions during the forecast period?
  • What are the opportunities in the global dementia associated with Alzheimer's disease market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Neuroprotection Market - Research Objectives and Research Approach

The comprehensive report on the global dementia associated with Alzheimer's disease market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global dementia associated with Alzheimer's disease market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global dementia associated with Alzheimer's disease market.

Table of Contents

1. Executive Summary

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Neuroprotection Market

4. Market Overview

  • 4.1. Market Segmentation
    • 4.1.1. Segment Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Neuroprotection Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Disease Prevalence & Incidence Rate Globally with Key Countries
  • 5.3. COVID-19 Pandemic Impact on Industry

6. Neuroprotection Market Analysis and Forecast, By Product

  • 6.1. Introduction and Definitions
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, By Product, 2017-2031
    • 6.3.1. Free Radical Trapping Agents (Antioxidants)
    • 6.3.2. Glutamate Antagonists (Anti-excitotoxic Agents)
    • 6.3.3. Apoptosis Inhibitors
    • 6.3.4. Anti-inflammatory Agents
    • 6.3.5. Neurotrophic Factors (NTFs)
    • 6.3.6. Metal Ion Chelators
    • 6.3.7. Stimulants
    • 6.3.8. Others
  • 6.4. Market Attractiveness, By Product

7. Global Neuroprotection Market Analysis and Forecast, by Application

  • 7.1. Introduction and Definitions
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Application, 2017-2031
    • 7.3.1. Prevention
    • 7.3.2. Treatment
  • 7.4. Market Attractiveness, by Application

8. Global Neuroprotection Market Analysis and Forecast, by Region

  • 8.1. Key Findings
  • 8.2. Market Value Forecast, by Region, 2017-2031
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3. Market Attractiveness, by Region

9. North America Neuroprotection Market Analysis and Forecast

  • 9.1. Introduction
    • 9.1.1. Key Findings
  • 9.2. Market Value Forecast, By Product, 2017-2031
    • 9.2.1. Free Radical Trapping Agents (Antioxidants)
    • 9.2.2. Glutamate Antagonists (Anti-excitotoxic Agents)
    • 9.2.3. Apoptosis Inhibitors
    • 9.2.4. Anti-inflammatory Agents
    • 9.2.5. Neurotrophic Factors (NTFs)
    • 9.2.6. Metal Ion Chelators
    • 9.2.7. Stimulants
    • 9.2.8. Others
  • 9.3. Market Value Forecast, by Application, 2017-2031
    • 9.3.1. Prevention
    • 9.3.2. Treatment
  • 9.4. Market Value Forecast, by Country, 2023-2031
    • 9.4.1. U.S.
    • 9.4.2. Canada
  • 9.5. Market Attractiveness Analysis
    • 9.5.1. By Product
    • 9.5.2. By Application
    • 9.5.3. By Country

10. Europe Neuroprotection Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, By Product, 2017-2031
    • 10.2.1. Free Radical Trapping Agents (Antioxidants)
    • 10.2.2. Glutamate Antagonists (Anti-excitotoxic Agents)
    • 10.2.3. Apoptosis Inhibitors
    • 10.2.4. Anti-inflammatory Agents
    • 10.2.5. Neurotrophic Factors (NTFs)
    • 10.2.6. Metal Ion Chelators
    • 10.2.7. Stimulants
    • 10.2.8. Others
  • 10.3. Market Value Forecast, by Application, 2017-2031
    • 10.3.1. Prevention
    • 10.3.2. Treatment
  • 10.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 10.4.1. Germany
    • 10.4.2. U.K.
    • 10.4.3. France
    • 10.4.4. Italy
    • 10.4.5. Spain
    • 10.4.6. Rest of Europe
  • 10.5. Market Attractiveness Analysis
    • 10.5.1. By Product
    • 10.5.2. By Application
    • 10.5.3. By Country/Sub-region

11. Asia Pacific Neuroprotection Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, By Product, 2017-2031
    • 11.2.1. Free Radical Trapping Agents (Antioxidants)
    • 11.2.2. Glutamate Antagonists (Anti-excitotoxic Agents)
    • 11.2.3. Apoptosis Inhibitors
    • 11.2.4. Anti-inflammatory Agents
    • 11.2.5. Neurotrophic Factors (NTFs)
    • 11.2.6. Metal Ion Chelators
    • 11.2.7. Stimulants
    • 11.2.8. Others
  • 11.3. Market Value Forecast, by Application, 2017-2031
    • 11.3.1. Prevention
    • 11.3.2. Treatment
  • 11.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.4.1. China
    • 11.4.2. Japan
    • 11.4.3. India
    • 11.4.4. Australia & New Zealand
    • 11.4.5. Rest of Asia Pacific
  • 11.5. Market Attractiveness Analysis
    • 11.5.1. By Product
    • 11.5.2. By Application
    • 11.5.3. By Country/Sub-region

12. Latin America Neuroprotection Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, By Product, 2017-2031
    • 12.2.1. Free Radical Trapping Agents (Antioxidants)
    • 12.2.2. Glutamate Antagonists (Anti-excitotoxic Agents)
    • 12.2.3. Apoptosis Inhibitors
    • 12.2.4. Anti-inflammatory Agents
    • 12.2.5. Neurotrophic Factors (NTFs)
    • 12.2.6. Metal Ion Chelators
    • 12.2.7. Stimulants
    • 12.2.8. Others
  • 12.3. Market Value Forecast, by Application, 2017-2031
    • 12.3.1. Prevention
    • 12.3.2. Treatment
  • 12.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.4.1. Brazil
    • 12.4.2. Mexico
    • 12.4.3. Rest of Latin America
  • 12.5. Market Attractiveness Analysis
    • 12.5.1. By Product
    • 12.5.2. By Application
    • 12.5.3. By Country/Sub-region

13. Middle East & Africa Neuroprotection Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, By Product, 2017-2031
    • 13.2.1. Free Radical Trapping Agents (Antioxidants)
    • 13.2.2. Glutamate Antagonists (Anti-excitotoxic Agents)
    • 13.2.3. Apoptosis Inhibitors
    • 13.2.4. Anti-inflammatory Agents
    • 13.2.5. Neurotrophic Factors (NTFs)
    • 13.2.6. Metal Ion Chelators
    • 13.2.7. Stimulants
    • 13.2.8. Others
  • 13.3. Market Value Forecast, by Application, 2017-2031
    • 13.3.1. Prevention
    • 13.3.2. Treatment
  • 13.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.4.1. GCC Countries
    • 13.4.2. South Africa
    • 13.4.3. Rest of Middle East & Africa
  • 13.5. Market Attractiveness Analysis
    • 13.5.1. By Product
    • 13.5.2. By Application
    • 13.5.3. By Country/Sub-region

14. Competition Landscape

  • 14.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  • 14.2. Market Share Analysis, by Company (2022)
  • 14.3. Company Profiles
    • 14.3.1. Daiichi Sankyo Company
      • 14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.1.2. Treatment Type Portfolio
      • 14.3.1.3. Financial Overview
      • 14.3.1.4. SWOT Analysis
      • 14.3.1.5. Strategic Overview
    • 14.3.2. Eli Lilly and Company
      • 14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.2.2. Treatment Type Portfolio
      • 14.3.2.3. Financial Overview
      • 14.3.2.4. SWOT Analysis
      • 14.3.2.5. Strategic Overview
    • 14.3.3. AbbVie Inc.
      • 14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.3.2. Treatment Type Portfolio
      • 14.3.3.3. Financial Overview
      • 14.3.3.4. SWOT Analysis
      • 14.3.3.5. Strategic Overview
    • 14.3.4. Dr. Reddy's Laboratories Ltd.
      • 14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.4.2. Treatment Type Portfolio
      • 14.3.4.3. Financial Overview
      • 14.3.4.4. SWOT Analysis
      • 14.3.4.5. Strategic Overview
    • 14.3.5. Teva Pharmaceutical Industries Ltd.
      • 14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.5.2. Treatment Type Portfolio
      • 14.3.5.3. Financial Overview
      • 14.3.5.4. SWOT Analysis
      • 14.3.5.5. Strategic Overview
    • 14.3.6. Novartis AG
      • 14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.6.2. Treatment Type Portfolio
      • 14.3.6.3. Financial Overview
      • 14.3.6.4. SWOT Analysis
      • 14.3.6.5. Strategic Overview
    • 14.3.7. AstraZeneca plc.
      • 14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.7.2. Treatment Type Portfolio
      • 14.3.7.3. Financial Overview
      • 14.3.7.4. SWOT Analysis
      • 14.3.7.5. Strategic Overview
    • 14.3.8. Astrocyte Pharmaceuticals, Inc.
      • 14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.8.2. Treatment Type Portfolio
      • 14.3.8.3. Financial Overview
      • 14.3.8.4. SWOT Analysis
      • 14.3.8.5. Strategic Overview
    • 14.3.9. F. Hoffmann-La Roche AG
      • 14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.9.2. Treatment Type Portfolio
      • 14.3.9.3. Financial Overview
      • 14.3.9.4. SWOT Analysis
      • 14.3.9.5. Strategic Overview
    • 14.3.10. Biogen Inc.
      • 14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.10.2. Treatment Type Portfolio
      • 14.3.10.3. Financial Overview
      • 14.3.10.4. SWOT Analysis
      • 14.3.10.5. Strategic Overview